Tocqueville Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Tocqueville Asset Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-4,000	Closed	-$390K	–	719
2020 Q3	$390K	Hold	4,000	–	–	0.01%	536
2020 Q2	$624K	Hold	4,000	–	–	0.01%	458
2020 Q1	$577K	Hold	4,000	–	–	0.01%	430
2019 Q4	$818K	Sell	4,000 -2,215	-36%	-$404K	0.01%	479
2019 Q3	$499K	Buy	6,215 +25	+0.4%	+$2.12K	0.01%	563
2019 Q2	$584K	Buy	+6,190	New	+$534K	0.01%	565

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Tocqueville Asset Management's RETA Position: Q4 2020 in Review

Tocqueville Asset Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2020, closing a stake of 4,000 shares — an estimated $390K sold.

Tocqueville Asset Management first reported a position in RETA in Q2 2019 and held it in 6 quarters. The position peaked at $818K in Q4 2019. 202 funds tracked by Wall St. Rank hold RETA as of Q4 2020.

Tocqueville Asset Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2020 after selling out during the quarter.
Tocqueville Asset Management sold 4,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2020, an estimated $390K.
Tocqueville Asset Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2019 and held it in 6 quarters.
Tocqueville Asset Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $818K in Q4 2019.
202 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2020.

Based on Tocqueville Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.